Bernstein Bank Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Bernstein Bank from $1,070.00 to $1,000.00 in a research note published on Tuesday morning.

REGN has been the subject of several other reports. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $983.65.

Regeneron Pharmaceuticals Trading Up 4.5 %

Shares of NASDAQ:REGN opened at $697.05 on Tuesday. The business’s 50-day moving average is $719.16 and its 200 day moving average is $918.90. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market capitalization of $76.60 billion, a P/E ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.86 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Adirondack Trust Co. increased its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the last quarter. Trust Co. of Vermont increased its position in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares in the last quarter. Nvwm LLC raised its stake in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 3.6% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.